Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG AAPL NFLX AMZN BIIB IBB WYNN TSLA ALXN CELG JAZZ ILMN CHTR AMGN COST FFIV SSYS GMCR Z
Nyse: V PXD ACT IBM UNP IVV LNKD MCK SPG LMT GS CMI MMM FDX TWC AGN CXO BA CVX XEC
New Highs: CLR AGN CXO KMB HP EQT CAT VNO SLB SRE NEE RRC EMN HES PEP DOV DTE WLL COP FANG

The Hot Industries

Independent Oil & Gas 5
Oil & Gas Drilling & Exploration 3
Diversified Machinery 2

The Hot Sectors

Basic Materials 11
Utilities 3
Industrial Goods 2

SPPI Stock Chart


SPPI
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

N/A
Monthly

Website:

http://www.sppirx.com

SPPI Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company’s commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

favicon

Wall Street Fundamentals Releases New In-Depth Stock Reports on ABIO, CHTP, NBS and SPPI

14 Apr 2014, 7:00 amThe Biotech Industry’s recent slide continued Friday as investors continued to shift their portfolios towards safer assets as we enter earnings season. On Friday, the iShares NASDAQ Biotechnology Index ...
favicon

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Spectrum Pharmaceuticals, Inc ...

8 Apr 2014, 2:11 pm
favicon

Northwest vs Feuerstein rhubarb round 3

28 Mar 2014, 11:42 amNorthwest Biotherapeutics ( NWBO -9.9% ) takes predictable exception to The Street's Adam Feuerstein regarding his bearish comments after CEO Linda Powers' DC-Vax presentation on March 27. The company insists that the statistical significance of the phase 3 trial results increases its chances of success not decreases as Mr. Feuerstein asserts. It also disputes his opinion that the trial has been ...
favicon

Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma

26 Mar 2014, 10:12 amLONDON, March 26, 2014 /PRNewswire/ -- On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended...